David Zimmerman
Optometrist · Nashville, TNNPI 1255744777
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,972 of the $7,770 with a category attached, or 76.9%. 24 manufacturers reported payments, led by Alcon at 27.5% of the total. Reporting peaked in 2019 at $2,698 and has fallen 74.6% since, to $685 in 2025. Among optometrist clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $33.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Glaukos Corporation$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$824
- AbbVie$724
- Johnson & Johnson Vision Care, Inc.$558
- Novartis$270
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$87511%
- Travel & lodging$80310%
- Food & beverage$5,97277%
- Education$1202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 60 | $2,138 |
| Glaukos Corporation | 8 | $1,245 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 27 | $824 |
| AbbVie(2 entities) | 22 | $724 |
| Johnson & Johnson Vision Care, Inc. | 12 | $558 |
| Novartis | 11 | $270 |
| Oyster Point Pharma, Inc. | 11 | $255 |
| Dompe US, Inc. | 11 | $246 |
| Bausch & Lomb Americas Inc. | 12 | $241 |
| Sun Pharmaceutical Industries Inc. | 10 | $226 |
| Tarsus Pharmaceuticals, Inc. | 9 | $217 |
| Harrow Eye, LLC | 5 | $145 |
| Eyevance Pharmaceuticals LLC | 8 | $106 |
| Carl Zeiss Meditec, Inc. | 2 | $104 |
| ABB Con-cise Optical Group LLC | 2 | $89 |
| Biotissue Holdings Inc. | 5 | $79 |
| Kala Pharmaceuticals, Inc. | 4 | $78 |
| Mallinckrodt Enterprises LLC | 2 | $63 |
| Shire North American Group Inc | 2 | $47 |
| Alcon Research LLC | 2 | $39 |
| Ocular Therapeutix, Inc. | 1 | $29 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $21 |
| Rxsight Inc | 1 | $20 |
| Maculogix, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,770 in reported general payments places this provider in the 95th percentile of 1,122 optometrist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 72 | $94,083 |
| XiidraLifitegrast | 30 | $55,852 |
| MieboPerfluorohexyloctane/Pf | 50 | $36,952 |
| Cyclosporine | 15 | $12,264 |
| TyrvayaVarenicline Tartrate | 16 | $9,625 |
| Loteprednol Etabonate | 19 | $2,340 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,130 |
| Fluorometholone | 16 | $1,393 |
| Latanoprost | 86 | $1,056 |
| Prednisolone Acetate | 33 | $1,008 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $693 |
| Timolol Maleate | 13 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $724 | $94,08372 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $241 | $92,80480 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $255 | $9,62516 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $824 | $2,34019 claims |
| AlconSimbrinza | $2,138 | $2,13011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,122 optometrist providers in Tennessee.
Other optometrist in Nashville
- Jeffrey SonsinoNashville$48K
- Richard DurocherNashville$18K
- Julianne KochNashville$8K
- C Wade Hyatt IiiNashville$8K
- James DuckloNashville$7K
- Bernard TekieleNashville$6K
- Jessica DurhamNashville$6K
- Marianne JohnsonNashville$6K
- William Parsley IiiNashville$6K
- Christopher LievensMemphis$566K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.